AffaMed Therapeutics nhasi yazivisa kuti DEXTENZA yakatenderwa kuMacau, China kuti irapwe kuzvimba kwemaziso uye kurwadziwa zvichitevera kuvhiyiwa kwemaziso. Muna 2020, AffaMed Therapeutics yakapinda muchibvumirano cherezinesi neOcular Therapeutix yekusimudzira uye kushambadzira kweDEXTENZA muGreater China, South Korea, uye nemimwe misika yeASEAN. DEXTENZA parizvino yakatenderwa kuUS kuti irapwe kuzvimba kwemaziso uye kurwadziwa zvichitevera kuvhiyiwa kwemaziso uye kurapwa kwekuvaviwa kwemaziso kunoenderana neallergic conjunctivitis.
Dr. Dayao Zhao, CEO weAffaMed akati: “Tinokurudzirwa nemutemo wehurumende yeMacau uye kushanda nesimba mukunyoresa mishonga mitsva yakavakirwa paruzivo rwakasimba rwekuongororwa kwekiriniki kubva kuongororo dzeOcular's FDA. Chikwata chedu chiri kugadzirira chikumbiro chekuwedzera chiratidzo chakatenderwa kuti chisanganise kurapwa kwemaziso itching ine chekuita neallergic conjunctivitis. Tiri kutarisira kutanga DEXTENZA uye kupa chigadzirwa kuvarwere muMacau nekukurumidza sezvinobvira. "
Nekugamuchira iyi mvumo, DEXTENZA inova yekutanga-yakasununguka-kuburitswa intracanalicular kuiswa muMacau ichiendesa inochengetedza-isina dosi yedexamethasone kwemazuva anosvika makumi matatu nekutonga kumwe chete.
ZVOKUBVA MUNYAYA INO:
- yekurapa kuzvimba kwemaziso uye kurwadziwa kunotevera kuvhiyiwa kwemaziso uye kurapwa kweiyo itching yemaziso ine chekuita neallergic conjunctivitis.
- Muna 2020, AffaMed Therapeutics yakapinda muchibvumirano cherezinesi neOcular Therapeutix yekusimudzira uye kushambadzira kweDEXTENZA muGreater China, South Korea, uye nemimwe misika yeASEAN.
- Nekugamuchira iyi mvumo, DEXTENZA inova yekutanga-yakasununguka-kuburitswa intracanalicular kuiswa muMacau ichiendesa inochengetedza-isina dosi yedexamethasone kwemazuva anosvika makumi matatu nekutonga kumwe chete.
